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OPINION/OPINIE
Atrial fibrillation - an old problem and an old solution
~RIAL fibrillation (AF) is a common arrhythmiaaffecting approximately 0,4% of the adult popu-lation. Prevalence rises to 2 - 4% in individuals
over 60 years of age. l ,2 There are many causes of AF,
rheumatic heart disease being one of the more promi-
nent. The combination of rheumatic heart disease and
AF is associated with a 17-fold increase in the rate of
cerebrovascular accidents compared with the rate in
those individuals who do not have valvular disease and
who are in sinus rhythm.3 The association berween AF
from other causes and strokes is not clear. The
Framingham study reported a 5-fold increase in
strokes in patients with chronic non-rheumatic AF
compared with patients in sinus rhythm.' However,
Kopecky er aI.' were un~ble to demonstrate any associ-
ation between strokes and lone AF. AF due to thyro-
toxicosis and hypertension has been associated with an
increased incidence of stroke.... Autopsy studies' sug-
gest that patients with AF and ischaemic heart disease
have a .greater chance of suffering from systemic
emboli than patients with ischaemic heart disease in
sinus rhythm. Clinical findings do not support this
observation, howeveL'
Not all strokes in patients with AF are due to
emboli. Clinical and radiological examination cannot
distinguish with certainty berween thrombi and throm-
bo-emboli lO and even autopsy studies are not always
conclusive." This has generated much controversy and
it has been suggested that the majority of strokes in AF
patients are due to atherosclerosis and that the AF
itself is simply a manifestation of this disease." Further
unresolved problems are those of asymptomatic cere-'
bral infarction in patients with chronic AF and its role
in the aetiology of multi-infarct dementia.
Computed tomography studies suggest that asymp-
tomatic infarcts are more common in patients with AF
compared with age-matched controls in sinus
rhythm. 13 These findings have not been confirmed, and
glucose intolerance may be a more important risk
factoL l4
The value of anticoagulation in patients with AF
and rheumatic heart disease is generally accepted.
During the 1950s and 1960s trials were conducted in
an attempt to assess its worth in cerebrovascular
disease. Anticoagulant therapy failed to provide any
benefit to patients and the incidence of side-effects was
high. In retrospect, these trials were poorly designed
from the point of view of defining end points and
exclusion criteria. They also attempted to cover too
many areas at once. I5-17
However, three recent trials,IB-20 all involving large
numbers of patients and statistically well planned, have
clearly demonstrated the advantages of anticoagulation
in patients with non-rheumatic AF. Two trials ..,20 com-
pared the effects of warfarin to those of placebo or
aspirin. Warfarin reduced the incidence of mortality
from vascular and thrombo-emboIic events in both
trials (overall mortality rates were 1% v. 50/0" and
2,2% v. 5,9%'0). In the Scandinavian trial," using
conventional levels of anticoagulation (target INR:
2,4 - 4,2), haemorrhagic side-effects reached 7%
(compared with 2% in the controls). In the Boston
trial,z° where the target INR was 1,7 - 2,5, major
haemorrhagic side-effects were similar in both arms,
but there was an impressive reduction in strokes
(0,41 % per year compared with 2,98% in the control
group). The third report concerned the ongoiJ g
'stroke prevention in AF' study.IB This work is mte
difficult to interpret, being a preliminary report will :l
showed that warfarin or aspirin separately were su~ _
rior to placebo. The rwo study arms remained blind j
and as yet no differences have been det<:cted betwe n
the rwo agents.
As might be expected, these trials also raisec a
number of questions. Two trials IB,l9 had arms involvi a
aspirin; in onel9 aspirin failed to reduce the inciden ;
of thrombo-embolic events. In the second,IB aspir .1
was shown to be of benefit, but this trial is ongoi. g
and the results are not conclusive. Aspirin may' e
expected to have a beneficial effect in patients wi 1
AF; estimates of embolic episodes resulting in strok s
range from 19% to 75% in these patients." A secOl j
unresolved issue is that of age, and the benefits f
using anticoagulants in patients over 75 is an UDr -
solved issue.
The Boston anticoagulation trial was notable for t ~
Iow dose of warfarin used~ an INR of 1,5 - 2,7 bei: s
considered therapeutic. Two strokes were recorded 1
the warfarin group of 212 patients compared with 3
strokes in the control group of 208 patients. The:
findings are in line with several other reports whic 1
indicate that anticoagulation at a Iow level is effe -
tive,22,23 and no doubt further trials will pinpoint ju [
what the optimum dosage of anticoagulant i .
Nevertheless, the message is clear: if a patient has A ~
and if there are no significant risk factors, then one h s
a good reason for administering anticoagulants.
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MEDICOLEGAL
Lessons frOnt the investigation into intravenous fluid-related
neonatal deaths
7
I t is a matter of record that during 1990 severalneonates died unexpectedly at three Johannesburgclinics. Cases were reviewed by the Attorney-'
General of the Transvaal and an inquest was ordered,
the purpose of which was to establish whether there was
criminal negligence on the part of any of the parties con-
cerned. The inquest examined 13 deaths which were
temporally related, were associated with positive blood
cultures or a clinical syndrome compatible with septi-
caemia, and which occurred in neonates who had
received one of two proprietary intravenous fluids as
part of their management.
While it was acknowledged that the intravenous
fluids from two or possibly three batches were found to
be contaminated, under the circumstances of an epi-
demic within intensive care units (lCUs) or high-care
areas, the Court found it impossible to determine
whether individual deaths might have been caused by an
injection of contaminated fluid or as a result of noso-
comial infection. The Court found in respect of all but
two of the deaths that there was no evidence of any act
or omission on the part of any person amounting to an
offence which caused the death, and in the case of the
remaining two deaths, the Court made an open finding.
As regards the source of the contamination of the intra-
venous fluids, the Court was unable to find negligence
on the part of the manufacturer and was satisfied that
internationally accepted procedures and standards had
been applied.
The epidemic created anguish on the part of the par-
ents and the doctors caring for the babies and, with
increasing intensity as the months went by, prompted
searches for the source of infection and reviews of infec-
tion control procedures by the clinics and the manufac-
turer concerned. At various times some of the ICU facil-
ities were closed in an attempt to eradicate the 'infec-
tions, and ultimately, when it became apparent that
some IV solutions were contaminated, the manufacturer
permanently closed the admixture unit in which the
solutions had been prepared.
It is worth considering that the health care team in a
simation like this includes doctors, nurses, dispensaries,
clinic administrators and the manufacmrer. What are
the lessons the health care team can learn from this
unformnate episode, which has been so costly in terms
oflives, time and money?
Accountability to parents
Perhaps on an emotional note, the first lesson is for the
clinic administrators and the manufacturer. Quite obvi-
ously, where there was a threat of litigation neither party
was prepared to accept responsibility for the deaths,
leaving grieving parents \vith a sense of abandonment.
While this aspect might be inevitable legalistically, it is
nevertheless extremely distressing for families.
Frustration was added to the families' sense of
abandonment by another legal inevitability, the time
required for investigation by the Attorney-General. In
this regard the health care team can do little other than
respond timeously and adequately to requests for clini-
cal details and affidavits.
Relationship between the manufacturers
and the health professionals
Historically, the preparation of the two products under
investigation was undertaken by the manufacruring firm
in its admixture unit as a service to the medical profes-
sion. Prior to this, the products were mixed by individu-
al hospitals and clinics, often in less than ideal circum-
stances.
Thousands of units of fluid were prepared by the
manufacturer over several years and used without inci-
dent by facilities in the private and academic sectors.
Unfortunately, the communication which was estab-
lished when the services of the admixmre unit were
engaged lapsed somewhat as the years passed. This is
probably not surprising because there was apparently
